On August 13, 2019 4SC AG (4SC, FSE Prime Standard: VSC) reported, that it received a single digit million Euro milestone payment from its partner Guangzhou Link Health Pharma Co., Ltd (Link Health) in accordance with the licensing and development agreement for the cancer therapeutic candidate 4SC-205 (Press release, 4SC, AUG 13, 2019, View Source [SID1234538646]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the 2016 agreement, Link Health received from 4SC the exclusive licensing rights for the development, regulatory submission and marketing of 4SC-205 in China, Hong Kong, Taiwan and Macao and is responsible for performing and financing the clinical development of 4SC-205.

Yan Song, Ph.D., CEO of Link Health, says: "We initiated a Phase I, open label, dose escalation trial to assess the safety, tolerability and pharmacokinetics of LH031 (4SC-205) orally administered in adult patients with advanced solid malignancies or lymphoma. Secondary objectives include to assess the drug candidate’s potential anti-cancer activity."

Jason Loveridge, Ph.D., CEO of 4SC, comments: "We are very pleased that our Chinese partner has successfully advanced 4SC-205 into the next stage of development and initiated the first clinical trial with our drug candidate in Asia. 4SC remains focused on advancing our core drug candidates resminostat and domatinostat, but nonetheless our strategy to monetize and advance non-core assets through partnerships continues to progress well."